Translocation (11;11)(p13- p15;q23) in a child with therapy-related acute myeloid leukemia following chemotherapy with DNA-topoisomerase II inhibitors for Langerhans cell histiocytosis

Cancer Genet Cytogenet. 2002 May;135(1):101-2. doi: 10.1016/s0165-4608(01)00638-0.

Abstract

We report a new case of therapy-related acute myeloid leukemia in a child with Langerhans cell histiocytosis. This patient was previously treated with a protocol of multidrug chemotherapy, containing a relatively low dose of etoposide (total dose of 900/m(2)). Twenty-six months after the end of the therapy, the patient returned to the hospital with fever and anemia. The white blood cell count was 53 x 10(9)/L. The bone marrow examination showed massive infiltration with French-American-British acute myeloid leukemia classification M4 blast cells. The patient did not respond to an intensive treatment with high dose ARA-C and idarubicin. He died 6 months later. The cytogenetic abnormality of the blast cells was a t(11;11)(p13 -15;q23), that has not been described before in a secondary leukemia case.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child, Preschool
  • Chromosomes, Human, Pair 11 / genetics*
  • Cytarabine / administration & dosage
  • Drug Therapy, Combination
  • Enzyme Inhibitors / adverse effects*
  • Etoposide / administration & dosage
  • Etoposide / adverse effects*
  • Fatal Outcome
  • Histiocytosis, Langerhans-Cell / drug therapy*
  • Humans
  • Idarubicin / administration & dosage
  • Karyotyping
  • Leukemia, Myelomonocytic, Acute / chemically induced
  • Leukemia, Myelomonocytic, Acute / drug therapy
  • Leukemia, Myelomonocytic, Acute / genetics*
  • Male
  • Neoplasms, Second Primary / chemically induced
  • Neoplasms, Second Primary / genetics*
  • Nuclear Pore Complex Proteins / genetics
  • Prednisolone / administration & dosage
  • Prednisolone / therapeutic use
  • Topoisomerase II Inhibitors*
  • Translocation, Genetic*
  • Vinblastine / administration & dosage
  • Vinblastine / therapeutic use

Substances

  • Enzyme Inhibitors
  • Nuclear Pore Complex Proteins
  • Topoisomerase II Inhibitors
  • nuclear pore complex protein 98
  • Cytarabine
  • Vinblastine
  • Etoposide
  • Prednisolone
  • Idarubicin